IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ryozo NAGAI et al.

Group Art Unit: 4131

Appl. No. : 10/511,274

Examiner : Nannette Holloman

I.A. Filed

: April 22, 2003

Confirmation No.: 6408

For

: MEDICAMENT FOR THERAPEUTIC TREATMENT OF

Confirmation No. : 0408

VASCULAR DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop <u>AMENDMENT</u>
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Further to the Information Disclosure Statement filed April 21, 2006 and in accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring to the attention of the Examiner the following co-pending U.S. application:

 U.S. Application No. 11/366,454, filed March 3, 2006, and entitled "Medicament having neovascularization promoting action", which was published as U.S. 2007/0049579.

Further to the U.S. Patent and Trademark Office's decision to partially waive the requirements under 37 C.F.R. § 1.98 (a)(2)(i) and (iii), a copy of the U.S. Patent

Application No. 10/511,274

Attorney Docket No. P26087

Application cited above is not enclosed herewith. However, if a copy is needed, the

Examiner is respectfully requested to contact the undersigned.

filed after a non-final Office Action on the merits. Accordingly, as set forth in 37 C.F.R.

Applicants note that this Supplemental Information Disclosure Statement is being

§ 1.17(p), Applicants provide herewith payment of the fee necessary for consideration of

this Information Disclosure Statement. If any other fee is deemed necessary, the Patent

and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

> Respectfully Submitted, Rvozo NAGAI et al.

Sean Myentagne Bruce H. Bernstein 47 9 20

August 29, 2008

GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place

Reston, VA 20191 (703) 716-1191

2